Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)

por Auerswald, Guenter, Djambas Khayat, Claudia, Stasyshyn, Oleksandra, Iosava, Genadi, Romashevskaya, Irina, López, Marta Julia, Seifert, Wilfried, Rogosch, Tobias
Publicado 2020

Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pedi...

por Djambas Khayat, Claudia, Iosava, Genadi, Romashevskaya, Irina, Stasyshyn, Oleksandra, Lopez, Marta Julia, Pompa, Maria Teresa, Rogosch, Tobias, Seifert, Wilfried
Publicado 2021

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety

por Mahlangu, Johnny, Levy, Howard, Kosinova, Marina V., Khachatryan, Heghine, Korczowski, Bartosz, Makhaldiani, Levani, Iosava, Genadi, Lee, Martin, Del Greco, Frank
Publicado 2021